Market Closed -
Bombay S.E.
06:19:06 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
2,133
INR
|
+3.26%
|
|
+14.12%
|
+12.40%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
220,202
|
210,953
|
244,012
|
281,714
|
224,319
|
361,301
|
-
|
-
|
Enterprise Value (EV)
1 |
207,591
|
200,080
|
232,521
|
256,351
|
207,663
|
361,301
|
361,301
|
361,301
|
P/E ratio
|
49.4
x
|
226
x
|
68.1
x
|
16.6
x
|
36.7
x
|
53.1
x
|
47.1
x
|
41.7
x
|
Yield
|
1.54%
|
1.61%
|
2.08%
|
1.8%
|
2.42%
|
1.42%
|
1.48%
|
1.6%
|
Capitalization / Revenue
|
7.04
x
|
6.54
x
|
7.63
x
|
8.59
x
|
6.9
x
|
10.7
x
|
9.9
x
|
9.04
x
|
EV / Revenue
|
7.04
x
|
6.54
x
|
7.63
x
|
8.59
x
|
6.9
x
|
10.7
x
|
9.9
x
|
9.04
x
|
EV / EBITDA
|
36.7
x
|
32.1
x
|
35.1
x
|
34.1
x
|
27.9
x
|
41.7
x
|
36.9
x
|
32.6
x
|
EV / FCF
|
204
x
|
63
x
|
45.7
x
|
36.3
x
|
51
x
|
44
x
|
51.5
x
|
41.4
x
|
FCF Yield
|
0.49%
|
1.59%
|
2.19%
|
2.75%
|
1.96%
|
2.27%
|
1.94%
|
2.41%
|
Price to Book
|
10.3
x
|
11.6
x
|
16.3
x
|
10.6
x
|
12.9
x
|
19.8
x
|
18.3
x
|
16.3
x
|
Nbr of stocks (in thousands)
|
169,406
|
169,406
|
169,406
|
169,406
|
169,406
|
169,406
|
-
|
-
|
Reference price
2 |
1,300
|
1,245
|
1,440
|
1,663
|
1,324
|
2,133
|
2,133
|
2,133
|
Announcement Date
|
5/20/19
|
5/18/20
|
5/18/21
|
5/16/22
|
5/17/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
31,281
|
32,244
|
31,989
|
32,780
|
32,517
|
33,648
|
36,493
|
39,953
|
EBITDA
1 |
6,008
|
6,572
|
6,953
|
8,273
|
8,043
|
8,671
|
9,804
|
11,089
|
EBIT
1 |
5,522
|
5,746
|
6,160
|
7,592
|
7,385
|
8,450
|
9,571
|
10,911
|
Operating Margin
|
17.65%
|
17.82%
|
19.26%
|
23.16%
|
22.71%
|
25.11%
|
26.23%
|
27.31%
|
Earnings before Tax (EBT)
1 |
6,827
|
3,058
|
5,505
|
7,790
|
8,364
|
9,325
|
10,390
|
11,703
|
Net income
1 |
4,454
|
932
|
3,582
|
16,947
|
6,107
|
6,063
|
7,678
|
8,656
|
Net margin
|
14.24%
|
2.89%
|
11.2%
|
51.7%
|
18.78%
|
18.02%
|
21.04%
|
21.67%
|
EPS
2 |
26.29
|
5.500
|
21.14
|
100.0
|
36.05
|
40.20
|
45.30
|
51.10
|
Free Cash Flow
1 |
1,081
|
3,346
|
5,337
|
7,761
|
4,402
|
8,213
|
7,018
|
8,725
|
FCF margin
|
3.46%
|
10.38%
|
16.68%
|
23.68%
|
13.54%
|
24.41%
|
19.23%
|
21.84%
|
FCF Conversion (EBITDA)
|
17.99%
|
50.91%
|
76.75%
|
93.81%
|
54.73%
|
94.72%
|
71.58%
|
78.68%
|
FCF Conversion (Net income)
|
24.27%
|
359.01%
|
149.02%
|
45.8%
|
72.08%
|
135.46%
|
91.4%
|
100.79%
|
Dividend per Share
2 |
20.00
|
20.00
|
30.00
|
30.00
|
32.00
|
30.30
|
31.53
|
34.20
|
Announcement Date
|
5/20/19
|
5/18/20
|
5/18/21
|
5/16/22
|
5/17/23
|
-
|
-
|
-
|
Fiscal Period: March |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
8,572
|
8,138
|
7,900
|
10,099
|
8,159
|
8,096
|
7,451
|
9,169
|
8,023
|
7,874
|
7,617
|
9,129
|
8,555
|
8,396
|
EBITDA
1 |
2,055
|
1,709
|
1,517
|
2,765
|
1,978
|
1,752
|
1,489
|
2,569
|
2,287
|
1,697
|
1,439
|
2,351
|
2,354
|
2,098
|
EBIT
1 |
1,878
|
1,530
|
1,340
|
2,589
|
1,799
|
1,599
|
1,331
|
2,406
|
2,123
|
1,526
|
1,275
|
2,339
|
2,049
|
1,898
|
Operating Margin
|
21.91%
|
18.81%
|
16.96%
|
25.64%
|
22.05%
|
19.75%
|
17.86%
|
26.24%
|
26.46%
|
19.37%
|
16.74%
|
25.62%
|
23.95%
|
22.61%
|
Earnings before Tax (EBT)
1 |
2,114
|
630.1
|
1,649
|
2,735
|
1,718
|
2,078
|
1,600
|
2,622
|
2,242
|
1,900
|
1,810
|
2,701
|
2,327
|
2,168
|
Net income
1 |
1,565
|
143.3
|
1,211
|
2,042
|
1,504
|
12,190
|
1,193
|
1,934
|
1,646
|
1,334
|
1,322
|
1,998
|
1,294
|
1,610
|
Net margin
|
18.26%
|
1.76%
|
15.33%
|
20.22%
|
18.43%
|
150.57%
|
16.01%
|
21.1%
|
20.51%
|
16.94%
|
17.36%
|
21.89%
|
15.13%
|
19.18%
|
EPS
|
9.240
|
0.8500
|
7.150
|
12.06
|
8.880
|
71.96
|
7.040
|
11.42
|
9.710
|
7.880
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/5/21
|
5/18/21
|
7/26/21
|
10/29/21
|
2/7/22
|
5/16/22
|
7/25/22
|
11/11/22
|
2/7/23
|
5/17/23
|
7/26/23
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
12,611
|
10,873
|
11,491
|
25,363
|
16,656
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
1,081
|
3,346
|
5,337
|
7,761
|
4,402
|
8,213
|
7,018
|
8,725
|
ROE (net income / shareholders' equity)
|
21.2%
|
22.8%
|
21.6%
|
81.8%
|
27.7%
|
37.7%
|
40.2%
|
40.9%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
126.0
|
107.0
|
88.50
|
157.0
|
103.0
|
108.0
|
116.0
|
131.0
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2,913
|
1,559
|
442
|
346
|
440
|
741
|
555
|
520
|
Capex / Sales
|
9.31%
|
4.84%
|
1.38%
|
1.06%
|
1.35%
|
2.2%
|
1.52%
|
1.3%
|
Announcement Date
|
5/20/19
|
5/18/20
|
5/18/21
|
5/16/22
|
5/17/23
|
-
|
-
|
-
|
Last Close Price
2,133
INR Average target price
2,141
INR Spread / Average Target +0.40% Consensus |
1st Jan change
|
Capi.
|
---|
| +12.40% | 4.33B | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|